Skip to content

Cerus CERS US — Non-Current Assets

Similar metrics at other companies

Agilysys logo
AGYSUS — Non-Current Assets
$15.33M-17.7%
PDF Solutions logo
PDFSUS — Non-Current Assets
$102.92M+53.9%
Taysha Gene Therapies, Inc. logo
TSHAUS — Non-Current Assets
$0
Lightwave Logic, Inc. logo
LWLGUS — Non-Current Assets
$9.41M
UFP Industries, Inc. logo
UFPIUS — Non-Current Assets
$1B+10.8%
Ceva logo
CEVAUS — Non-Current Assets
$939K-43.0%

Other financials

Income statement

See full
Revenue$53.7M+24.1%
Operating income-$354.0K+94.0%
Net income-$1.6M+78.7%
EPS (diluted)-$0.01+75.0%

Balance sheet

See full
Cash & equivalents$27.9M+43.0%
Total debt$45.0M-43.3%
Total equity$67.6M+21.7%
Total assets$222.9M+7.8%

Cash flow

See full
Operating cash flow-$3.0M-261%
CapEx$233.0K+108%
Free cash flow-$3.3M-243%

Valuation

See full
Market cap$573.06M+124%
Enterprise value$590.17M+86.7%
P/S2.9×-1.0×

Profitability

See full
Gross margin64%
Operating margin-6.2%-2.1pp
Net margin-9.8%-2.8pp
FCF margin3.5%+1.9pp

Returns & leverage

See full
Return on equity-15.5%-5.6pp
Debt / equity0.7×-0.8×
Current ratio1.6×-0.7×

Where this comes from

Reported directly by Cerus in its filing.

Tagged under the XBRL concept us-gaap:NoncurrentAssets.

The official record: Cerus’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Cerus's us — non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Cerus's US — non-current assets?
Cerus (CERS) reported US — non-current assets of $5.47M in Q4 2025.
How has Cerus's US — non-current assets changed year-over-year?
Cerus's US — non-current assets decreased by 19.6% year-over-year, from $6.81M to $5.47M.
What does US — non-current assets mean?
This metric represents the total value of long-term assets held by the company specifically within the United States geographic segment. These assets typically include property, plant, equipment, and intangible assets that support the commercialization and distribution of blood safety systems in the domestic market. Tracking this figure helps investors assess the capital intensity and infrastructure investment required to sustain the company's US-based operations.